148 related articles for article (PubMed ID: 31280227)
1. Grade 3 and 4 Toxicity Profiles During Therapy of Childhood Acute Lymphoblastic Leukemia.
Zawitkowska J; Lejman M; Zaucha-Prażmo A; Drabko K; Płonowski M; Bulsa J; Romiszewski M; Mizia-Malarz A; Kołtan A; Derwich K; Karolczyk G; Ociepa T; Ćwiklińska M; Trelińska J; Owoc-Lempach J; Niedźwiecki M; Kiermasz A; Kowalczyk J
In Vivo; 2019; 33(4):1333-1339. PubMed ID: 31280227
[TBL] [Abstract][Full Text] [Related]
2. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
3. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
[TBL] [Abstract][Full Text] [Related]
4. Impact of DARC, GSDMA and CXCL2 polymorphisms on induction toxicity in children with acute lymphoblastic leukemia: A complementary study.
Gatineau-Sailliant S; Glisovic S; Gagné V; Laverdière C; Leclerc JM; Silverman LB; Sinnett D; Krajinovic M; Pastore Y
Leuk Res; 2019 Nov; 86():106228. PubMed ID: 31590117
[No Abstract] [Full Text] [Related]
5. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.
Domenech C; Suciu S; De Moerloose B; Mazingue F; Plat G; Ferster A; Uyttebroeck A; Sirvent N; Lutz P; Yakouben K; Munzer M; Röhrlich P; Plantaz D; Millot F; Philippet P; Dastugue N; Girard S; Cavé H; Benoit Y; Bertrandfor Y;
Haematologica; 2014 Jul; 99(7):1220-7. PubMed ID: 24727815
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.
Maxwell RR; Cole PD
Curr Hematol Malig Rep; 2017 Jun; 12(3):176-186. PubMed ID: 28317081
[TBL] [Abstract][Full Text] [Related]
7. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
8. [Leukemia and malnutrition. II. The magnitude of maintenance chemotherapy as a prognostic factor in the survival of patients with standard-risk acute lymphoblastic leukemia].
Lobato-Mendizábal E; Ruiz-Argüelles GJ
Rev Invest Clin; 1990; 42(2):81-7. PubMed ID: 2267453
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol.
Aslam S; Ameer S; Shabana NA; Ahmed M
Sci Rep; 2021 Dec; 11(1):23757. PubMed ID: 34887513
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
[TBL] [Abstract][Full Text] [Related]
11. Acute lymphoblastic leukemia.
Chan KW
Curr Probl Pediatr Adolesc Health Care; 2002 Feb; 32(2):40-9. PubMed ID: 11951089
[TBL] [Abstract][Full Text] [Related]
12. Induction failure in acute lymphoblastic leukemia of childhood.
Silverman LB; Gelber RD; Young ML; Dalton VK; Barr RD; Sallan SE
Cancer; 1999 Mar; 85(6):1395-404. PubMed ID: 10189148
[TBL] [Abstract][Full Text] [Related]
13. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
14. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.
Kliman D; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Narayanan S; Nevill T; Power M; Sanford D; Song K; Sutherland H; Toze C; Abou Mourad Y
Leuk Lymphoma; 2017 Apr; 58(4):909-915. PubMed ID: 27561638
[TBL] [Abstract][Full Text] [Related]
16. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy.
Rivera GK; Raimondi SC; Hancock ML; Behm FG; Pui CH; Abromowitch M; Mirro J; Ochs JS; Look AT; Williams DL
Lancet; 1991 Jan; 337(8733):61-6. PubMed ID: 1670723
[TBL] [Abstract][Full Text] [Related]
17. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.
Denton CC; Rawlins YA; Oberley MJ; Bhojwani D; Orgel E
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29218844
[TBL] [Abstract][Full Text] [Related]
18. Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study.
Hori H; Kudoh T; Nishimura S; Oda M; Yoshida M; Hara J; Tawa A; Usami I; Tanizawa A; Yumura-Yagi K; Kato K; Kobayashi R; Komada Y; Matsuo K; Horibe K;
Int J Clin Oncol; 2017 Apr; 22(2):387-396. PubMed ID: 27858183
[TBL] [Abstract][Full Text] [Related]
19. [Clinical features and prognosis of children with lymphoblastic lymphoma].
Jin L; Zhang R; Huang S; Yang J; Duan YL; Zhang YH
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):138-42. PubMed ID: 22780934
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia.
Sun W; Orgel E; Malvar J; Sposto R; Wilkes JJ; Gardner R; Tolbert VP; Smith A; Hur M; Hoffman J; Rheingold SR; Burke MJ; Wayne AS
Pediatr Blood Cancer; 2016 Nov; 63(11):1943-8. PubMed ID: 27437864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
